Table 4. National Cancer Institute Manufactured Drugs.
| Drug name | Pharmaceutical collaborators | Outcome and year |
|---|---|---|
| 17-AAG | Pharmacia | IND withdrawn 2012 |
| 5-azacitidine | Pharmion/Celgene | FDA approved 2004 (Vidaza-Pharmion/ Celgene) |
| 9-Aminocamptothecin (9-AC) | Pharmacia | IND withdrawn 2005 |
| BL22 | IND withdrawn 2008 | |
| CAI | IND withdrawn 2010 | |
| Carboxypeptidase | Microbiological Research Establishment (CAMR)/Protherics | FDA approved 2012 (Voraxaze-Protherics/BTG) |
| Chimeric 14.18 | NCI development ongoing (United Therapeutics, Inc) | |
| COL-3 | Collagenex Pharmaceuticals, Inc | IND withdrawn 2010 |
| Depsipeptide (romidepsin) | Celgene | FDA approved 2009 (Istodax-Celgene) |
| Fenretinide | R.W. Johnson Pharmaceuticals | NCI development ongoing |
| Flavopiridol (Alvocidib) | NCI development ongoing | |
| gp100:209-217(210M) peptide | NCI development ongoing | |
| Halichondrin B analog (eribulin) | Eisai, Inc | FDA approved 2010 (Halaven-Eisai, Inc) |
| Homoharringtonine | IND withdrawn 2008 | |
| LMB-2 | NCI development ongoing | |
| MART-1:26-35(27L) peptide | IND withdrawn 2008 | |
| Nelarabine (506U78) | GlaxoSmithKline | FDA approved 2005 (Arranon-GlaxoSmithKline) |
| O6-BG | NCI development ongoing | |
| PANVAC | Therion | NCI development ongoing |
| Proteinase 3:PR1 peptide | IND withdrawn 2010 | |
| PS-341 (bortezomib) | Millennium | FDA approved 2003 (Velcade-Millennium) |
| rF-gp100P209 (recombinant fowlpox-gp100P209) | Therion | IND withdrawn 2012 |
| Sodium phenylbutyrate | Elan Pharmaceutical Research Corporation/Virium Pharmaceuticals | IND withdrawn 2008 |
| Suramin | Parke Davis and Company | IND withdrawn 2008 |
| Thymidine | IND withdrawn 2004 | |
| XL119 (becatecarin, rebeccamycin analog) | Exelixis/Bristol Myers Squibb | IND withdrawn 2008 |
FDA indicates US Food and Drug Administration; IND, investigational new drug; NCI, National Cancer Institute.